Novavax Inc (NVAX) Stock Analysis

Novavax Inc (NVAX) is a publicly traded company in the HEALTHCARE sector. It trades at $10.21, carries a market capitalization of $1.73B. This page summarizes the public market data, fundamentals, and frequently asked questions for NVAX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Novavax Inc currently has a Neutral sentiment score of 0.10.

About Novavax Inc

Novavax, Inc. is a biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the research and development of innovative vaccines targeting serious infectious diseases. Leveraging its proprietary protein-based nanoparticle technology, Novavax has cultivated a robust pipeline, notably including its advanced COVID-19 vaccine candidate, which has received considerable attention amid the ongoing global health crisis. The company's commitment to addressing pressing public h...

GNG Research Analysis

GNG Research scores Novavax Inc (NVAX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NVAX.

Frequently Asked Questions

Does NVAX pay dividends?

Novavax Inc (NVAX) does not currently pay a regular dividend.

What is NVAX's market cap?

Novavax Inc (NVAX) has a market capitalization of $1.73B with a current stock price of $10.21.